

![]() |
Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting |
|
Authors | ||
Published in | Clinical infectious diseases. 2019 | |
Abstract | Hepatitis C virus (HCV) amongst people living in detention (PLD) is typically high in many countries including Switzerland, where it is estimated that the HCV prevalence rate is between 5.7% and 6.2%. In Switzerland, the existing screening strategy involves routine screening of PLD who indicate they are from HCV high-risk populations based on questionnaire responses upon entry to the detention center, rather than an offer to screen all PLD. | |
Keywords | Cost-Benefit Analysis — Hepatitis C — Mass Screening — Prisons — Antiviral Agents | |
Identifiers | DOI: 10.1093/cid/ciz088 PMID: 30715266 | |
Full text | ||
Structures | ||
Research groups | Etudes et traitement de l'hépatite C et B (554) Groupe Desmeules Jules (pharmacologie/toxicologie) (567) | |
Citation (ISO format) | GIRARDIN, François et al. Modelling the Impact and Cost-Effectiveness of Extended Screening and Treatment with Direct-Acting Antivirals in a Swiss Custodial Setting. In: Clinical Infectious Diseases, 2019. doi: 10.1093/cid/ciz088 https://archive-ouverte.unige.ch/unige:115852 |